Lentiviral Vector Market Poised to Hit $29.41 Billion by 2029 with Accelerating Growth Trends

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts

Lentiviral Vector Market Size Growth Forecast: What to Expect by 2025?
In recent years, the lentiviral vector market has seen substantial growth. It is projected to expand from a market size of $14.37 billion in 2024 to an impressive $16.62 billion in 2025, indicating a compound annual growth rate (CAGR) of 15.7%. Factors contributing to the historic period's growth include the increasing prevalence of genetic disorders, the demand for gene delivery, expansion of biotech and pharmaceutical industries, investment in clinical trials, and regulatory approvals.

How Will the Lentiviral Vector Market Size Evolve and Grow by 2029?
The market size of lentiviral vectors is predicted to experience swift expansion in the upcoming years, enroute to reaching $29.41 billion in 2029, with a compound annual growth rate (CAGR) of 15.3%. This growth projected for the forecast period can largely be credited to various factors such as the advancement in personalized medicines, innovations in gene editing, increasing demand for therapies targeting rare diseases, the adoption of lentiviral vectors, funding for genomic medicine, and the emphasis on manufacturing scalability. Key trends expected during the forecast period encompass the widened scope of research and development, incorporation in CAR-T cell therapy, the emergence of next-gen vectors, utilization in vaccine development, and the evolution of production technologies.

View the full report here:
https://www.thebusinessresearchcompany.com/report/lentiviral-vector-global-market-report

What Drivers Are Propelling the Growth of Lentiviral Vector Market Forward?
The escalating occurrence of chronic ailments is anticipated to boost the progress of the lentiviral vectors market. Chronic ailments are medical issues that usually develop slowly over the course of time and often last for years or even a lifetime. The rise in such diseases is attributed to factors such as aging populations, unhealthy lifestyles, urbanization, and environmental influences. Lentiviral vectors provide versatile and effective methods for creating vaccines and therapies for chronic diseases, addressing unfulfilled medical needs, and enhancing patient outcomes. For example, the British Heart Foundation, a UK-based cardiovascular research charity, stated in September 2024, that about 7.6 million people in the UK suffer from heart and circulatory diseases. This includes around 4 million men and 3.6 million women suffering from these conditions. These diseases account for nearly 27% of all deaths in the UK, leading to over 170,000 deaths every year, or approximately 480 deaths daily. This amounts to one death every three minutes. Hence, the escalating occurrence of chronic ailments is fueling the growth of the lentiviral vectors market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=14742&type=smp

Which Emerging Trends Are Transforming the Lentiviral Vector Market in 2025?
Prominent businesses in the lentiviral vectors market are prioritizing the development of LV vector generation platforms like LentiSure, to improve the productivity and reliability of lentivirus vector production for cell-based immuno-oncology treatments. LentiSure is a production platform for LV vectors that are used in these therapies, with a specific focus on bolstering efficiency and stability in vector creation. For example, Yposkesi sk pharmteco, a viral vectors manufacturer based in France, introduced LentiSure in May 2023. This sophisticated platform is aimed at improving the production of lentiviral (LV) vectors and strengthening the resilience and efficiency of lentivirus production. It directly addresses the soaring demand for reliable and cost-effectively scalable viral-vector manufacturing technologies needed in cell and gene therapies. It provides a consistently high-quality product, with average titers at cell culture harvest at 10e7 IG/mL bioreactor volume, guaranteeing increased productivity and success for cell therapy developers.

What Are the Key Segments in the Lentiviral Vector Market?
The lentiviral vector market covered in this report is segmented -

1) By Product Type: Kits, Reagents And Consumables
2) By Indication: Cancer, Genetic Disorder, Infectious Disease, Veterinary Disease, Other Indications
3) By End User: Biotechnology Companies, Pharmaceutical Companies, Contract Research Organization (CRO), Academic And Research Institutes

Subsegments:
1) By Kits: Lentiviral Transduction Kits, Lentiviral Packaging Kits, Lentiviral Vector Production Kits
2) By Reagents and Consumables: Lentiviral Packaging Reagents, Lentiviral Vector Concentration Reagents, Transfection Reagents for Lentiviral Vectors

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=14742&type=smp

Who Are the Key Players Shaping the Lentiviral Vector Market's Competitive Landscape?
Major companies operating in the lentiviral vector market are Pfizer Inc., AbbVie Inc., Bayer AG, Sanofi SA, Bristol Myers Squibb Company, Thermo Fisher Scientific Inc., AstraZeneca plc, Novartis AG, GlaxoSmithKline plc (GSK), Eli Lilly and Company, Agilent Technologies Inc., Amgen Inc., Merck KGaA, Lonza Group Ag, Cytiva, Charles River Laboratories, Bio-Rad Laboratories Inc., Promega Corporation, Takara Bio Inc., Sino Biological Inc., OriGene Technologies Inc., Applied Biological Materials Inc., Oxford Biomedica, Sirion-Biotech GmbH, Yposkesi

What Geographic Markets Are Powering Growth in the Lentiviral Vector Market?
North America was the largest region in the lentiviral vector market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the lentiviral vector market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=14742

"This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work."

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.